Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIOCNASDAQ:HTGMQNASDAQ:IONMNASDAQ:TCBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIOCBiocept$0.97$0.32▼$27.00$1.14M0.69764,067 shs751,400 shsHTGMQHTG Molecular Diagnostics$0.00$0.00▼$0.10N/A2.72,575 shsN/AIONMAssure$0.05$0.04$0.03▼$0.55$150K1.858,693 shs2 shsTCBPTC Biopharm$0.68-55.8%$0.68$0.50▼$195.20$279K0.01146,324 shs5.33 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIOCBiocept0.00%0.00%0.00%0.00%0.00%HTGMQHTG Molecular Diagnostics0.00%0.00%0.00%0.00%-96.00%IONMAssure0.00%-2.25%+47,700.00%+47,700.00%-99.37%TCBPTC Biopharm0.00%0.00%0.00%-65.08%-99.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIOCBioceptN/AN/AN/AN/AN/AN/AN/AN/AHTGMQHTG Molecular DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/AIONMAssureN/AN/AN/AN/AN/AN/AN/AN/ATCBPTC Biopharm1.2833 of 5 stars3.50.00.00.00.00.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIOCBiocept 0.00N/AN/AN/AHTGMQHTG Molecular Diagnostics 0.00N/AN/AN/AIONMAssure 0.00N/AN/AN/ATCBPTC Biopharm 3.00Buy$48.006,948.46% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIOCBiocept$25.86M0.00N/AN/A$15.60 per share0.00HTGMQHTG Molecular Diagnostics$6.37M0.00N/AN/AN/ANaNIONMAssure$149K1.01N/AN/A($41.04) per share0.00TCBPTC Biopharm$4.76M0.06N/AN/A$519.58 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIOCBiocept-$32.09M-$58.45N/AN/AN/AN/A-468.87%-118.41%N/AHTGMQHTG Molecular Diagnostics-$21.59MN/A0.00N/AN/AN/AN/AN/AN/AIONMAssure-$26.08MN/A0.00∞N/A-25,178.32%N/A-249.78%6/3/2025 (Estimated)TCBPTC Biopharm-$7.35MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIOCBioceptN/AN/AN/AN/AN/AHTGMQHTG Molecular DiagnosticsN/AN/AN/AN/AN/AIONMAssureN/AN/AN/AN/AN/ATCBPTC BiopharmN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIOCBiocept2.881.811.70HTGMQHTG Molecular DiagnosticsN/AN/AN/AIONMAssureN/A0.200.20TCBPTC Biopharm0.671.12N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIOCBioceptN/AHTGMQHTG Molecular DiagnosticsN/AIONMAssure3.33%TCBPTC Biopharm16.25%Insider OwnershipCompanyInsider OwnershipBIOCBiocept1.61%HTGMQHTG Molecular Diagnostics2.60%IONMAssure3.80%TCBPTC Biopharm15.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIOCBiocept502.63 million2.58 millionNot OptionableHTGMQHTG Molecular Diagnostics902.21 million2.16 millionNot OptionableIONMAssure1303.13 million3.02 millionNot OptionableTCBPTC Biopharm80410,00028,000Not OptionableBIOC, HTGMQ, TCBP, and IONM HeadlinesRecent News About These CompaniesTC BioPharm Holdings PLC (TCBPY)May 11, 2025 | investing.comTCBP Announces Grant of European Patent for Targeting of Microbial, Oncological, and Viral Indications using Modified Gamma Delta T CellsApril 9, 2025 | finance.yahoo.comTC BioPharm: TCBP Announces Transition from Nasdaq to OTC MarketsMarch 24, 2025 | finanznachrichten.deTC BioPharm to be delisted from Nasdaq, moves to OTC MarketsMarch 23, 2025 | uk.investing.comTC Biopharm announces transition to OTC Markets from NasdaqMarch 22, 2025 | markets.businessinsider.comTC BioPharm Stock Crashes On Nasdaq Delisting: Retail Expresses FrustrationMarch 21, 2025 | msn.comTC BioPharm Transitions from Nasdaq to OTC Markets Amid Delisting NoticeMarch 21, 2025 | tipranks.comTCBP Announces Transition from Nasdaq to OTC MarketsMarch 21, 2025 | prnewswire.comTC Biopharm launches cost reduction initiativesMarch 19, 2025 | finance.yahoo.comTCBP Announces Outsourcing Initiatives, Reducing Burn Rate and OverheadMarch 18, 2025 | prnewswire.comTC BioPharm: TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical CompanyMarch 5, 2025 | finanznachrichten.deTCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical CompanyMarch 5, 2025 | prnewswire.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for WeekFebruary 28, 2025 | msn.comTCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO ForumFebruary 20, 2025 | prnewswire.comTC BioPharm: TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical TrialFebruary 13, 2025 | finanznachrichten.deTCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical TrialFebruary 13, 2025 | prnewswire.comTC BioPharm: TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical TrialFebruary 11, 2025 | finanznachrichten.deTC Falls Despite Cohort B TrialsFebruary 11, 2025 | baystreet.caTC Biopharm completes initial Cohort B patient dosing in ACHIEVE trialFebruary 10, 2025 | markets.businessinsider.comTCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical TrialFebruary 10, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIOC, HTGMQ, TCBP, and IONM Company DescriptionsBiocept NASDAQ:BIOCBiocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.HTG Molecular Diagnostics NASDAQ:HTGMQHTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Assure NASDAQ:IONM$0.05 0.00 (0.00%) As of 05/29/2025Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. It offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures. The company delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing services to support surgeons and medical facilities during invasive procedures. Assure Holdings Corp. is based in Englewood, Colorado.TC Biopharm NASDAQ:TCBP$0.68 -0.86 (-55.78%) Closing price 03/21/2025Extended Trading$0.68 0.00 (0.00%) As of 03/21/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
